Plus Therapeutics Inc (PSTV) FinancialsPSTVPlus Therapeutics Inc

Plus Therapeutics Inc (PSTV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumable, accounting for 94.3% of total sales, equivalent to $663.00K. Another important revenue stream is Other products. Understanding this composition is critical for investors evaluating how PSTV navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Plus Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2203.65%, while the net margin is -2191.24%. These profitability ratios, combined with a Return on Equity (ROE) of -614.05%, provide a clear picture of how effectively PSTV converts its operational activities into shareholder value.

In the context of the broader market, PSTV competes directly with industry leaders such as ACTU and ABVC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, PSTV's gross margin of N/A stands against ACTU's N/A and ABVC's N/A. Such benchmarking helps identify whether Plus Therapeutics Inc is trading at a premium or discount relative to its financial performance.

No quarterly financial snapshot was provided, so latest-quarter revenue, earnings, and margin trends cannot be assessed here. The available data only indicates ongoing commercialization and clinical progress rather than reported financial results.